Abstract. Sperm-associated antigen 9 (SPAG9) is a recently characterized oncoprotein that is considered to be involved in several forms of malignant tumor. However, its biological function and expression pattern in human osteosarcoma have not yet been elucidated. In the present study, SPAG9 expression was analyzed in 58 cases of human osteosarcoma by immunohistochemistry. The results demonstrated that SPAG9 was overexpressed in 63.8% (37/58) of osteosarcoma tissues, while normal bone tissues exhibited negative SPAG9 expression. SPAG9 small interfering RNA was employed in the U2OS cell line, which has high endogenous expression, and SPAG9 transfection was performed in the MG63 cell line, which has low endogenous expression. MTT and Matrigel invasion assays demonstrated that SPAG-9-knockdown significantly reduced U2OS cell invasion and proliferation, while SPAG9 transfection enhanced MG63 cell proliferation and invasion. Furthermore, it was observed that SPAG9 positively regulated cyclin D1, phosphorylated-c-Jun NH2-terminal kinase (JNK) and JunD expression. Treatment with the JNK inhibitor, SP600125, abolished the upregulatory effect of SPAG9 on JunD. Taken together, the present study identified SPAG9 as a critical oncoprotein involved in osteosarcoma proliferation and invasion, possibly functioning through JNK-JunD signaling.
Introduction
Osteosarcoma is a common adolescent cancer, which comprises ~20% of all forms of primary bone cancer (1) . The survival rate for osteosarcoma has remained relatively poor for the last 30 years and is ~60% worldwide (2, 3) . The identification of novel oncogenic targets and the underlying molecular events that promote the malignant growth, invasion and metastasis of osteosarcoma may aid the development of successful treatment strategies for patients with the disease (4) (5) (6) .
Cancer/testis (CT) antigens are proteins that are typically expressed in the human germ line. A number of studies have demonstrated that these proteins are upregulated in various forms of cancer, and may therefore be targeted by therapeutic cancer vaccines (7) .
Sperm-associated antigen 9 (SPAG9) was originally identified as a novel member of the CT antigen family, and functions as a scaffolding protein involved in the activation of the c-Jun NH2-terminal kinase (JNK) signaling pathway (8) (9) (10) (11) (12) . Previous studies have reported that SPAG9 is overexpressed in various types of human cancer, including breast, thyroid and cervical cancer, and colorectal carcinoma (13) (14) (15) (16) (17) . SPAG9 small interfering RNA (siRNA) treatment in cancer cells was reported to inhibit tumor cell growth and invasion. In addition, SPAG9 protein expression in tumors was observed to be associated with circulating SPAG9 antibodies in the serum of patients with early-stage breast and cervical cancer (13, 14) , indicating its potential application in early cancer detection. To date, the expression pattern and biological function of SPAG9 in human osteosarcoma remains unknown.
In the present study, the expression pattern of SPAG9 in 58 osteosarcoma specimens was investigated. In addition, the potential effects of SPAG9 on cell proliferation and invasion were examined in U2OS and MG63 osteosarcoma cell lines. Immunohistochemistry. Paraffin-embedded osteosarcoma tissues were cut into 4-µm thick sections prior to immunostaining. Immunostaining was performed using the EliVision™ Plus Immunohistochemical Detection kit (Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China). The sections were deparaffinized in xylene, rehydrated with graded alcohol and subsequently boiled in citrate buffer (pH 6.0) for 2 min with an autoclave. Endogenous peroxidase was blocked by 3% hydrogen peroxide, and normal animal serum (Pierce Biotechnology, Inc., Rockford, IL, USA) was used to reduce non-specific binding. Tissue sections were incubated with polyclonal rabbit anti-SPAG9 antibody (dilution, 1:300; #ab12331; Abcam, Cambridge, MA, USA) overnight at 4˚C. Rabbit immunoglobulin (dilution, 1:300; #ab150062; Abcam) was used (at the same concentration as the antigen-specific antibody) as a negative control. Primary staining was followed by incubation with biotinylated anti-horseradish peroxidase secondary antibodies (dilution, 1:2,000; #ab34885; Abcam). The peroxidase reaction was developed with 3,3'-diaminobenzidine (Fuzhou Maixin Biotech Co., Ltd.). Counterstaining with hematoxylin was performed and the sections were dehydrated in ethanol prior to mounting.
Materials and methods

Patients
Immunostaining of SPAG9 was scored on a semiquantitative scale by evaluating the percentage and intensity of tumor cells according to a previous study (19) . A total of 400 tumor cells were counted by microscope and the percentage of positively-stained cells was calculated. The intensity of SPAG9 staining was scored as follows: 0, negative/weak; 1, moderate; and 2, strong. Percentage scores were assigned as follows: 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. The scores of each tumor sample were multiplied to give a final score between 0-8, and a tumor sample score of ≥4 was considered to indicate overexpression.
Quantitative polymerase chain reaction (qPCR).
Template DNA was obtained from U2OS and MG63 cells. qPCR was performed using the SYBR ® Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) in a total volume of 20 µl on a 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The cycling conditions were as follows: 95˚C for 30 sec; 40 cycles of 95˚C for 30 sec and 60˚C for 30 sec. A dissociation step was performed to generate melting curves to confirm the specificity of the amplification. PCR was repeated three times. Expression levels of the analyzed genes were normalized to the expression of β-actin. The fold change of gene expression was calculated by the 2 -ΔΔCq method (20) . The sequences of the primer pairs were as follows: SPAG9 forward, 5'-GCT TTT GAT CGC AAT ACA GAA TCT C-3'; and reverse, 5'-AAC TTC CCG ACC CAT TCC TAGT-3'; and β-actin forward, 5'-ATA GCA CAG CCT GGA TAG CAA CGT AC-3' and reverse, 5'-CAC CTT CTA CAA TGA GCT GCG TGT G-3'. The primers were designed by Oligo 7 software (www.oligo.net).
Western blot analysis. Total protein was extracted from cells using cell lysis buffer (Pierce Biotechnology, Inc.) and quantified using the Bradford method. Samples were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and were transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA) where they were incubated overnight at 4˚C with antibodies against SPAG9 (dilution, 1:1,000; #ab12331; Abcam), cyclin D1 (dilution, 1:1,000; #2978; Cell Signaling Technology, Inc., Danvers, MA , USA), phosphorylated (p)-JNK (dilution, 1:1,000; #4668; Cell Signaling Technology, Inc.), JNK (dilution, 1:1,000; #9252; Cell Signaling Technology, Inc.), JunD (dilution, 1:1,000; #5000; Cell Signaling Technology, Inc.) and glyceraldehyde 3-phosphate dehydrogenase (dilution, 1:1,000; #2118; Cell Signaling Technology, Inc.). Following incubation with peroxidase-coupled anti-mouse/rabbit immunoglobulin G (Cell Signaling Technology, Inc.) at 37˚C for 2 h, bound proteins were visualized using ECL Western Blotting Substrate (Pierce Biotechnology, Inc.) and detected using a BioImaging system (UVP Inc., Upland, CA, USA). Relative protein levels were quantified using β-actin as a loading control and ImageJ 1.48v software (National Institutes of Health, Bethesda, MD, USA).
Transwell invasion and MTT assays.
Cell invasion was performed in a 24-well Transwell chamber (8-µm pore size; Costar, Corning, NY, USA). The insert was coated with 50 ml Matrigel (dilution, 1:3; BD Bioscience, Franklin Lakes, NJ, USA). U2OS cells were trypsinized following transfection with negative control or SPAG9 siRNA for 48 h at 37˚C, and were subsequently transferred to the upper chamber in 100 ml serum-free medium containing 1x10 5 cells and incubated for 24 h. The lower chamber was filled with medium supplemented with 10% fetal bovine serum (Pierce Biotechnology, Inc.) as chemoattractant. The membranes were fixed and stained using 0.1% crystal violet. The number of invading cells were counted in five randomly selected high-power fields (magnification, x400) under a microscope. All experiments were performed in triplicate.
For the MTT assay, the cells were plated in 96-well plates at a concentration of ~2,000 cells per well and cultured for 3 days. For quantification of cell viability, 20 µl 5 mg/ml MTT (thiazolyl blue) solution was added to each well and incubated for 4 h at 37˚C. The medium was removed from each well and the resulting MTT formazan was solubilized in 200 µl dimethyl sulfoxide. The solution was measured spectrophotometrically at 490 nm.
Statistical analysis. SPSS version 11.5 (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses. The χ 2 test was used to examine associations between SPAG9 expression and clinicopathological factors, whilst Student's t-test was used to compare invasive cells and colony numbers between control and SPAG9 depletion cells. All P-values are based on two-sided statistical analysis, and P<0.05 was considered to indicate a statistically significant difference.
Results
Expression pattern of SPAG9 in osteosarcoma tissues.
In the normal bone tissues, SPAG9 staining was negative (Fig. 1A) . By contrast, SPAG9 overexpression was observed in 37 out of 58 (63.8%) human osteosarcoma tissues (Fig. 1B-D) , while no staining was observed in sections from the same specimens incubated with non-immune rabbit immunoglobulin. SPAG9 was primarily localized in the cytoplasm of the osteosarcoma cells. The association between SPAG9 protein expression and clinicopathological factors was analyzed, and no association was identified between SPAG9 expression and age, gender, pathological classification or location (Table I) .
Biological functions of SPAG9 in osteosarcoma cells.
To determine the biological functions of SPAG9 in osteosarcoma Table I . Association between SPAG9 and clinicopathological features. cell lines, the present study initially examined SPAG9 protein expression in the U2OS and MG63 cell lines. It was observed that SPAG9 expression was potent in the U2OS cells and weak in the MG63 cells ( Fig. 2A) . To examine the effect of SPAG9 on cell proliferation and invasion, siRNA-mediated SPAG9-knockdown was performed in the U2OS cell line and plasmid transfection was performed in the MG63 cell line. As presented in Fig. 2B , SPAG9 siRNA decreased SPAG9 protein and mRNA expression in the U2OS cells, and plasmid transfection upregulated SPAG9 expression in the MG63 cells. The MTT assay was employed to examine the role of SPAG9 on cell proliferation. The results demonstrated that SPAG9 siRNA inhibited the cell growth rate in the U2OS cells, and SPAG9 transfection upregulated cell proliferation in the MG63 cells (Fig. 3A) . A Transwell assay was employed to characterize the effect of SPAG9 on cell invasion. As presented in Fig. 3B , SPAG9 depletion significantly inhibited cell invasion in the U2OS cell line (control vs. siRNA, 119±12 vs. 48±6; P<0.05) and its transfection accelerated cell invasion in the MG63 cell line (empty vector vs. plasmid, 83±9 vs. 156±12; P<0.05).
SPAG9
Clinical -------------------------------------------
SPAG9 regulates JunD expression in osteosarcoma cells.
Consistent with a previous study (19) , the results of the present study indicated that SPAG9 is a regulator of osteosarcoma cell proliferation and invasion. It has previously been reported that SPAG9 is involved in JNK signaling (21) . To investigate the mechanisms underlying this association, the current study examined the protein level of JunD following SPAG9-knockdown and transfection. As presented in Fig. 4A , (Fig. 4A) . Treatment with the JNK inhibitor, SP600125 (20 nM, 3 h post-transfection), abolished the upregulatory effect of SPAG9 on JunD (Fig. 4B) , indicating that SPAG9 may regulate the malignant biological behavior of osteosarcoma cells through JNK-JunD regulation.
Discussion
In the present study, it was observed that the level of SPAG9 expression was elevated in osteosarcoma tissues compared with that in normal bone specimens. In vitro experiments in osteosarcoma cell lines demonstrated that SPAG9 depletion inhibited proliferation and invasion, while SPAG9 transfection accelerated proliferation and invasion. In addition, it was observed that SPAG9 was able to regulate JunD expression.
SPAG9 has previously been identified to be overexpressed in various types of cancer, including lung, breast, renal, hepatocellular and colorectal cancer (13, 17, 19, 21, 22) . The current study observed negative SPAG9 staining in normal bone tissues, and positive cytoplasmic SPAG9 expression in 63.8% (37/58) of osteosarcoma tissues, which was consistent with previous studies (19,. A number of studies have described the role of SPAG9 in cancer cell proliferation and provided accumulating evidence that characterizes SPAG9 as an oncoprotein regulating cell invasion. It was reported that SPAG9 siRNA knockdown inhibited cell invasion and proliferation in renal, lung and colorectal carcinoma (13, 21, (23) (24) (25) . To gain insight into the function of SPAG9 in osteosarcoma progression, SPAG9 expression was knocked down in the U2OS cell line and upregulated in the MG63 cell line in the present study. Consistent with a former study (19, 26, 27) , it was demonstrated that SPAG9 depletion significantly inhibited cell proliferation and invasion, whilst SPAG9 plasmid transfection upregulated proliferation and invasion. These results suggested that SPAG9 serves an important role in osteosarcoma progression and may function as a biomarker for malignant behavior.
In the current study, the molecular pathway through which SPAG9 promotes osteosarcoma invasion and proliferation was also investigated. It was observed that SPAG9 was involved in JNK signaling; thus, JNK activation and its downstream target JunD, which serves as a link between JNK and cancer progression, was examined. Using western blot analysis, it was demonstrated that SPAG9 siRNA treatment downregulated p-JNK and JunD protein expression, whilst SPAG9 plasmid transfection upregulated the level of p-JNK and JunD. JunD is a component of the activator protein-1 transcription factor complex, which is important in cancer progression (28). A previous study reported that JunD activated cell proliferation via upregulation of cyclin D1 proteins (29) , and was also demonstrated to activate matrix metalloproteinase (MMP)-7 and MMP-9 transcription (30, 31) . MMP-7 and MMP-9 have been suggested to be critical for the metastatic and invasive potential in human malignancies, including osteosarcoma (32) (33) (34) (35) . Thus, when combined, these results suggest that SPAG9 may induce osteosarcoma cell proliferation and invasion through JNK-JunD signaling. Furthermore, a previous study reported that inhibition of JNK signaling facilitates flavonoid-induced apoptosis in osteosarcoma cells via downregulation of JunD, indicating that JunD functions as an oncoprotein during osteosarcoma progression (36) .
In conclusion, the present study established that SPAG9 is overexpressed in human osteosarcoma tissues. The results demonstrated that SPAG9 facilitated osteosarcoma cell proliferation and invasion, possibly through regulation of JNK-JunD signaling. Based on these findings, it may be concluded that SPAG9 is an important oncogene and may function as a potential therapeutic target in human osteosarcoma.
